Welcome to our dedicated page for Agilent Technologies SEC filings (Ticker: A), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agilent Technologies Inc. (NYSE: A) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports when available, and other filings that describe Agilent’s financial condition, governance changes, and capital markets activities.
Agilent uses Form 8-K to report material events such as quarterly financial results and executive leadership changes. For example, the company has filed 8-Ks to furnish earnings press releases for fiscal quarters, explaining revenue, net income, segment performance for the Life Sciences and Diagnostics Markets Group, Agilent CrossLab Group, and Applied Markets Group, and to discuss the use of non-GAAP financial measures. Separate 8-K filings describe the resignation of a chief financial officer, the appointment of an interim CFO, and the subsequent appointment of a new senior vice president and chief financial officer, including related compensation and equity awards.
Through its filings, Agilent explains why it presents non-GAAP financial information, stating that these measures are intended to provide meaningful supplemental insight into operational performance and to facilitate comparisons with historical results and other companies. The company notes that non-GAAP figures exclude items such as restructuring and amortization, are monitored alongside GAAP results, and may differ from similar measures used by other issuers.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that highlight key points, such as changes in leadership, segment trends, and the rationale behind non-GAAP adjustments. Users can quickly locate current reports, review disclosures about executive appointments and compensation arrangements, and understand how Agilent communicates its financial performance and governance decisions to regulators and investors.
Agilent Technologies is asking stockholders to vote at its March 18, 2026 annual meeting on four key items: electing four directors, approving executive pay on an advisory basis, ratifying PricewaterhouseCoopers as auditor, and amending the charter to declassify the Board over three years.
The company highlights strong governance practices, including an independent chair, majority voting for directors, board self-assessments, proxy access, and extensive stockholder engagement. After a 2025 stockholder proposal supporting declassification, the Board is now recommending moving to annual director elections, fully effective for all directors in 2029.
Agilent reports fiscal 2025 revenue of $6.9 billion, up 6.7% from 2024, with non‑GAAP operating margin at 25.7% and non‑GAAP diluted EPS of $5.59, up 5.7%. Total shareholder return rose 13.2% versus 21.5% for the S&P 500. The proxy describes a pay‑for‑performance program where 82–91% of named executive officer compensation is at risk, short‑term incentive payouts ranged from 92% to 108%, and 2023–2025 performance stock units paid out at 64%–118% of target based on EPS and relative TSR.
The filing also details a CFO transition, interim compensation for the acting CFO, and a new CFO package, plus planned 2026 changes simplifying incentives, shifting long‑term awards toward performance share units tied to three‑year relative TSR, and eliminating stock options.
Agilent Technologies is asking stockholders to vote at its 2026 annual meeting on electing four directors, approving executive pay on an advisory basis, ratifying PricewaterhouseCoopers as auditor, and amending its certificate of incorporation to declassify the board over three years. If the declassification proposal passes, all directors would stand for annual elections beginning in 2029.
The proxy outlines a largely independent board, an independent chair, majority voting for directors, proxy access, and policies against hedging, short selling and pledging company stock. It highlights ongoing shareholder engagement, including outreach to holders of about 65% of shares and broad support for declassifying the board after a 2025 stockholder proposal.
The filing also reviews director and CEO-level compensation structures, emphasizing pay-for-performance with most executive pay “at risk,” use of annual and long‑term incentives tied to revenue, margins, EPS and relative total shareholder return, and changes to the CFO role in 2025 with related transition and sign‑on awards.
Agilent Technologies, Inc. reported an amendment to an insider ownership filing for its vice president and corporate controller. The officer’s directly held common stock was corrected to 32,153.3546 shares following previously reported transactions. The original report had shown 31,526.6872 shares, so this amendment adds back shares that were understated due to an administrative error. The company states that only the holdings total is revised and that there are no changes to the underlying transactions previously reported.
Agilent Technologies, Inc. files its annual report describing a global business focused on life sciences, diagnostics and applied markets. The company provides instruments, software, services and consumables that support the entire laboratory workflow, serving pharmaceutical, biopharmaceutical, diagnostics, clinical, academic, government, chemical, food, environmental and forensics customers.
In November 2024 Agilent reorganized into three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets, and recast historical segment data to match this structure. Life Sciences and Diagnostics Markets combines liquid chromatography and mass spectrometry platforms with diagnostics, genomics, cell analysis and specialty contract development and manufacturing services, including BIOVECTRA and nucleic acid solutions.
Agilent CrossLab provides services, consumables, software and automation that are largely vendor neutral, while Applied Markets focuses on instruments and software for chemical, energy, advanced materials, food and environmental testing. As of October 31, 2025, Agilent employed approximately 18,100 people worldwide, with major R&D and manufacturing sites across the U.S., Europe and Asia.
Agilent Technologies director reports stock sale. A director of Agilent Technologies, Inc. reported selling 2,600 shares of common stock on 12/01/2025 at a weighted average price of $149.812 per share, with individual sale prices ranging from $149.80 to $149.84. After this transaction, the director beneficially owns 4,973.028 shares of Agilent common stock. This total includes 23.092 shares acquired through the company’s dividend reinvestment plan in transactions exempt under Rule 16a-11, which the director has elected to defer.
Agilent Technologies’ senior vice president reported a routine share transaction related to equity compensation. On 11/26/2025, the executive surrendered 208 shares of Agilent common stock to the company at a price of $154.37 per share to cover tax withholding on vesting restricted stock units, as allowed under Rule 16b-3. After this tax-related share surrender, the reporting person beneficially owned 11,639.0318 shares of Agilent common stock directly.
Agilent Technologies, Inc. reported an insider equity transaction by a Senior Vice President. On 11/26/2025, the executive surrendered 280 shares of common stock to Agilent to satisfy tax liabilities arising from the vesting of restricted stock units, as permitted under Rule 16b-3. The shares were valued at $154.37 each for this tax withholding transaction.
After this event, the executive beneficially owned 26,593.9266 shares of Agilent common stock directly and 2,607.6856 shares indirectly through a spouse. This is an administrative tax-related transaction rather than an open-market purchase or sale.
Agilent Technologies, Inc. reported an insider transaction by its President and CEO, who is also a director. On 11/26/2025, the executive surrendered 1,948 shares of common stock to Agilent at $154.37 per share to cover tax liabilities arising from the vesting of restricted stock units under Rule 16b-3.
After this tax-related share surrender, the executive beneficially owns 66,539 shares of Agilent common stock in direct ownership. This filing reflects a routine administrative transaction to satisfy taxes rather than an open-market sale.
Agilent Technologies, Inc. officer and Senior Vice President reported a routine equity transaction on Form 4. On 11/26/2025, the reporting person surrendered 300 shares of Agilent common stock to the company at a price of $154.37 per share to cover tax liabilities arising from the vesting of restricted stock units under Rule 16b-3. After this tax-related surrender, the reporting person beneficially owned 14,207.2469 shares of Agilent common stock, held directly.